How to Fight US Insurance Denials for Osteoporosis Treatment

Osteoporosis affects 10.2 million US adults, with another 43.9 million living with low bone mass. Despite clear guidelines from the American Association of Clinical Endocrinologists (AACE), American College of Physicians (ACP), and Endocrine Society, insurers routinely deny medications like Prolia (denosumab), Evenity (romosozumab), Forteo (teriparatide), Tymlos (abaloparatide), and Reclast (zoledronic acid IV). They also restrict DEXA scan frequency and deny kyphoplasty for vertebral fractures. The reasons are often financial rather than medical: anabolic agents and biologics cost $2,000–$4,000 per month, while generic alendronate costs $10–$30. Insurers impose step therapy, ignore very-high-risk criteria, cite outdated FDA black-box warnings, and delay imaging that would document disease progression. This guide shows you how to challenge those denials with the specific guidelines, trials, and policy language insurers must respect.

Why Insurers Deny Osteoporosis Treatment

Insurers use a handful of denial templates, often copying and pasting policy language without regard to your clinical history:

1. "Must try oral bisphosphonates first" (step therapy for Prolia, Evenity, Forteo, Tymlos, or Reclast IV).

The denial states that you haven't failed alendronate, risedronate, or ibandronate before the plan will cover a biologic or anabolic agent—even if you have severe osteoporosis (T-score ≤–3.0), a recent fragility fracture, declining bone density on oral therapy, or documented esophageal disease (stricture, Barrett's, dysphagia) that makes swallowing a bisphosphonate unsafe.

2. "Not very-high-risk per medical policy" (Evenity, Forteo, Tymlos).

The insurer claims you don't meet criteria for an anabolic agent. They may ignore your prior hip or spine fracture, your T-score of –3.1, your FRAX 10-year major osteoporotic fracture (MOF) probability of 28%, or the fact that you fractured while already on bisphosphonate therapy—all markers of very-high risk under AACE 2020 and 2024 guidelines.

3. "Evenity black-box warning applies" (cardiovascular contraindication).

The denial invokes Evenity's boxed warning for myocardial infarction and stroke, either claiming you have a cardiovascular history (when you don't) or stating the drug is "too risky" in general. The black-box warning restricts use only in patients with MI or stroke within the past 12 months; it does not prohibit Evenity in patients with remote or well-controlled cardiac disease or no cardiac history at all.

4. "Forteo lifetime two-year limit reached" or "osteosarcoma risk."

The plan invokes an old policy capping teriparatide at 24 months lifetime. The FDA removed both the two-year duration limit and the osteosarcoma black-box warning in November 2020 (label revision 021318s053) after post-marketing surveillance in over 200,000 patients found no human osteosarcoma signal. Many insurers still cite outdated policies.

5. "DEXA not medically necessary" or "must wait 24 months."

Medicare LCD L39268 and commercial policies often default to a two-year DEXA interval. The denial ignores ISCD 2019 official positions allowing follow-up scans at intervals shorter than 24 months when clinically indicated—for example, to confirm rapid bone loss, monitor treatment response in very-high-risk patients, or assess vertebral fractures by vertebral fracture assessment (VFA).

6. "Kyphoplasty is experimental" or "conservative therapy not exhausted."

Insurers deny vertebroplasty and kyphoplasty for acute vertebral compression fractures, demanding 6–12 weeks of "conservative care" first or calling the procedure investigational—despite VAPOUR trial data, American Academy of Orthopaedic Surgeons appropriateness criteria, and Medicare national coverage determination (NCD 150.11).

The Citations Insurers Respect

When you appeal, name these documents explicitly. Insurers respect peer-reviewed guidelines, FDA label updates, and landmark trials published in high-impact journals:

Guidelines and Policy Statements

• AACE Clinical Practice Guideline for Osteoporosis 2020 (updated 2024): Defines very-high fracture risk (T-score ≤–3.0, fracture within 12 months, multiple fractures, fracture on therapy, or FRAX MOF >30%) and recommends anabolic therapy first-line for very-high-risk patients.
• American College of Physicians Clinical Guideline 2023 (Annals of Internal Medicine): Recommends bisphosphonates as initial pharmacologic treatment for most postmenopausal women but explicitly lists denosumab, teriparatide, and romosozumab as second-line or alternative agents when bisphosphonates are contraindicated or not tolerated.
• Endocrine Society Clinical Practice Guideline 2019 (JCEM) and 2020 statement on denosumab discontinuation (JCEM): Endorses denosumab, anabolics, and IV zoledronic acid; emphasizes that stopping denosumab requires transition to bisphosphonate within 6 months to prevent rebound vertebral fractures.
• International Society for Clinical Densitometry (ISCD) Official Positions 2019: Supports DEXA intervals shorter than 24 months when medically necessary (e.g., glucocorticoid therapy, monitoring high-risk patients, confirming rapid bone loss).
• Bone Health & Osteoporosis Foundation (BHOF) Clinician's Guide 2022: Summarizes fracture-risk stratification, treatment thresholds, and drug sequencing; cites post-fracture care gap (only ~20% of women with hip fracture receive osteoporosis therapy within one year).

Pivotal Clinical Trials (with Journal and Year)

• FREEDOM trial (New England Journal of Medicine, 2009): Denosumab (Prolia) 60 mg every 6 months reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% versus placebo over 3 years in postmenopausal women with osteoporosis.
• FRAME trial (NEJM, 2016): Romosozumab (Evenity) 210 mg monthly for 12 months reduced new vertebral fractures by 73% and clinical fractures by 36% versus placebo; no excess cardiovascular events versus placebo at 12 months.
• ARCH trial (NEJM, 2017): Romosozumab for 12 months followed by alendronate reduced vertebral fractures by 48%, clinical fractures by 19%, and hip fractures by 38% compared to alendronate alone; a numerical imbalance in cardiovascular serious adverse events (2.5% romosozumab vs. 1.9% alendronate) led to the black-box warning restricting use in MI/stroke within 12 months.
• VERO trial (Lancet, 2018): Teriparatide (Forteo) reduced vertebral fractures by 56% (hazard ratio 0.44) compared to risedronate in postmenopausal women with severe osteoporosis, demonstrating superiority of anabolics over oral bisphosphonates in high-risk patients.
• HORIZON-Pivotal Fracture Trial (NEJM, 2007): Zoledronic acid (Reclast) 5 mg IV annually reduced vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% versus placebo.
• ACTIVE trial (Lancet, 2016): Abaloparatide (Tymlos) 80 mcg daily for 18 months reduced new vertebral fractures by 86% and nonvertebral fractures by 43% versus placebo.
• VAPOUR trial (Lancet, 2016): Balloon kyphoplasty for acute vertebral compression fractures provided statistically significant and clinically meaningful pain reduction and improved function compared to nonsurgical management at 1 month and sustained at 3 months.

FDA Label and Policy Updates

• Forteo (teriparatide) label revision November 2020 (NDA 021318s053): FDA removed the black-box warning for osteosarcoma and the recommendation to limit lifetime use to two years, based on 15-year post-marketing data showing no human osteosarcoma cases attributable to teriparatide.
• Medicare LCD L39268 (DEXA coverage): Allows bone-density testing at intervals less than 24 months when medically necessary—e.g., monitoring glucocorticoid therapy, confirming therapeutic response, assessing rapid bone loss.
• Medicare NCD 150.11 (vertebral augmentation): Covers kyphoplasty for acute vertebral compression fractures due to osteoporosis when certain clinical criteria are met.

How to Argue Against Each Major Denial Reason

"Must Try Oral Bisphosphonates First"

What to write in your appeal:

1. Cite AACE 2020/2024 very-high-risk criteria. If you meet any of the following, guidelines support anabolic or denosumab therapy without requiring bisphosphonate failure:

- T-score ≤–3.0 at the spine, total hip, or femoral neck

- Fragility fracture within the past 12 months

- Fracture while on bisphosphonate therapy (indicating treatment failure)

- Multiple prior fragility fractures

- FRAX 10-year MOF probability >30% or hip fracture probability >4.5%

Example language: "AACE 2020 Clinical Practice Guideline (page 14, Table 4) defines very-high fracture risk and recommends anabolic therapy first-line for these patients. My T-score is –3.1 at the femoral neck, and I sustained a vertebral compression fracture three months ago. Requiring oral bisphosphonate step therapy delays guideline-concordant care for a patient who already meets criteria for an anabolic agent."

2. Document contraindications or intolerance to oral bisphosphonates. ACP 2023 explicitly lists denosumab and anabolics as alternatives when bisphosphonates cannot be used. Present:

- Esophageal stricture, Barrett's esophagus, achalasia, or severe dysphagia (oral bisphosphonates require upright posture for 30–60 minutes and can cause esophagitis, ulceration, or perforation).

- Chronic kidney disease stage 4–5 (eGFR <30 mL/min) or acute kidney injury: oral bisphosphonates dose-adjust poorly; Reclast and Prolia also require caution, but Prolia does not require dose adjustment for renal impairment.

- Prior severe upper-GI adverse events on alendronate or risedronate (e.g., hospitalization for esophagitis, severe reflux despite PPI, documented gastric ulcer on EGD).

Example: "I was hospitalized in [date] with bisphosphonate-induced esophagitis confirmed by EGD, which showed severe ulceration. ACP 2023 guideline (Recommendation 2) endorses denosumab as an alternative when bisphosphonates are contraindicated. My gastroenterologist has documented that I cannot safely swallow oral bisphosphonates."

3. Cite trial superiority for very-high-risk patients. The VERO trial (Lancet 2018) proved teriparatide superior to risedronate (HR 0.44 for vertebral fracture). FREEDOM showed denosumab superior to placebo with 68% vertebral and 40% hip fracture reduction. If you are at very high risk, these agents are not "alternatives of last resort"—they are the evidence-based first choice.

Example: "The VERO trial (Lancet 2018) demonstrated teriparatide reduced vertebral fractures by 56% compared to risedronate in women with severe osteoporosis. I have a T-score of –3.0 and two prior fragility fractures. Step therapy that delays anabolic treatment exposes me to additional fracture risk that evidence-based care would prevent."

"Not Very-High-Risk per Medical Policy"

What to write in your appeal:

1. List every AACE 2020/2024 very-high-risk criterion you meet and attach documentation:

- DEXA report showing T-score ≤–3.0

- Radiology reports of fragility fractures (spine X-ray or MRI showing compression fractures, wrist/hip/humerus fracture reports)

- FRAX calculation print-out showing MOF >30% or hip >4.5% (use the official FRAX tool at sheffield.ac.uk/FRAX and include prior fracture, parental hip fracture, glucocorticoid use, smoking, alcohol)

- Trabecular bone score (TBS) if available; TBS <1.20 indicates degraded microarchitecture and independently predicts fracture

2. Emphasize fracture on therapy. If you broke a bone while taking a bisphosphonate, you have treatment failure—the strongest indicator for switching to an anabolic or denosumab. AACE 2020 explicitly names "fracture occurring while on approved osteoporosis therapy" as very-high-risk.

Example: "I sustained a vertebral compression fracture in [month/year] while taking alendronate 70 mg weekly for 18 months. This constitutes treatment failure. AACE 2020 guideline (page 14) lists 'fracture on therapy' as a very-high-risk criterion warranting anabolic therapy. Continuing the same class of drug that failed to prevent my fracture is not evidence-based care."

3. Cite the post-fracture care gap and morbidity. Bone Health & Osteoporosis Foundation 2022 data show that after a hip fracture, only ~20% of women receive osteoporosis treatment within a year, and one-year mortality is 20–25%. Vertebral fractures double mortality risk and lead to chronic pain, kyphosis, height loss, and restrictive lung disease. Denying effective therapy after a fracture has life-threatening consequences.

"Evenity Black-Box Warning Applies"

What to write in your appeal:

1. Quote the FDA label verbatim. Evenity's prescribing information (black-box warning, April 2019) states: "EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year." If you have not had an MI or stroke in the past 12 months, the black-box warning does not apply to you.

Example: "The denial states that Evenity is contraindicated due to cardiovascular risk. The FDA black-box warning restricts Evenity only in patients with MI or stroke within the preceding 12 months. I have no history of MI or stroke. My last echocardiogram [date] and stress test [date] were normal. The denial misapplies the label."

2. Cite FRAME trial cardiovascular data. FRAME (NEJM 2016) compared romosozumab to placebo over 12 months and found no excess cardiovascular events in the romosozumab group. The cardiovascular signal appeared in ARCH (NEJM 2017), where romosozumab was compared to active treatment (alendronate) and showed a numerical imbalance (2.5% vs. 1.9% cardiovascular serious adverse events). The absolute excess risk was small, the confidence interval crossed 1.0, and the finding may reflect a protective effect of bisphosphonates rather than harm from romosozumab. AACE 2020/2024 and ACP 2023 still endorse Evenity for very-high-risk patients without recent MI/stroke.

3. Emphasize fracture risk outweighs cardiovascular concern. If you have a T-score ≤–3.0, multiple fractures, or fracture on therapy, your immediate fracture risk is high. Hip fracture carries 20–25% one-year mortality; vertebral fracture doubles mortality. If you have no MI/stroke history and your cardiovascular risk is low or controlled, the fracture-risk reduction (73% vertebral, 36% clinical fracture) justifies Evenity use.

Example: "My 10-year ASCVD risk score is 6.2% (low). I have never had a heart attack or stroke. However, my FRAX 10-year hip fracture probability is 8.1%, and I fractured a vertebra six months ago. The risk of another fracture far exceeds any cardiovascular concern. AACE 2020 recommends Evenity for very-high-risk patients like me, and the black-box warning does not apply."

"Forteo Lifetime Two-Year Limit Reached" or Osteosarcoma Risk

What to write in your appeal:

1. Cite the November 2020 FDA label update. In supplement 021318s053, the FDA removed the black-box warning for osteosarcoma and the recommendation to limit use to two years, based on 15-year epidemiologic data from over 200,000 patients showing no causal link between teriparatide and osteosarcoma in humans. (The original warning was based on rat studies, where rats received doses 3–60 times the human dose for most of their lifespan—a scenario irrelevant to human use.)

Example: "The denial states I have reached a 'lifetime two-year limit' on Forteo. The FDA removed this limitation in November 2020 (label revision s053) and removed the osteosarcoma black-box warning after post-marketing surveillance found no human osteosarcoma cases. The plan's policy is outdated and contradicts current FDA labeling."

2. Explain clinical need for extended or repeat anabolic therapy. Some patients require more than 24 months of teriparatide (e.g., very severe osteoporosis, malabsorption, ongoing glucocorticoid therapy, intolerance to all antiresorptive agents). Endocrine Society 2019 acknowledges that anabolic therapy may be extended or repeated when clinically indicated, especially if bone density declines after stopping or if the patient cannot tolerate bisphosphonates as follow-on therapy.

3. Offer alternative anabolic if insurer will not budge. If the plan refuses to remove the Forteo cap, request Tymlos (abaloparatide) or Evenity instead—both are anabolic/bone-forming agents with similar efficacy, and neither carries a duration cap.

"DEXA Not Medically Necessary" or "Must Wait 24 Months"

What to write in your appeal:

1. Cite ISCD 2019 Official Positions. ISCD explicitly states that follow-up DEXA intervals shorter than 24 months are appropriate when needed to guide treatment decisions—for example:

- Monitoring glucocorticoid-induced osteoporosis (rapid bone loss can occur within 3–6 months)

- Confirming response to anabolic therapy (to decide whether to continue, switch, or add antiresorptive)

- Assessing rapid bone loss in early menopause or after discontinuing hormone therapy

- Vertebral fracture assessment (VFA) to detect asymptomatic vertebral compression fractures

Example: "Medicare LCD L39268 states that DEXA may be covered at intervals less than 23 months when medically necessary. I am on high-dose prednisone (20 mg daily) for lupus, which causes rapid bone loss. ISCD 2019 Official Positions recommend monitoring BMD at 6–12 month intervals during glucocorticoid therapy. Delaying DEXA until 24 months from my last scan prevents timely adjustment of osteoporosis treatment."

2. Document falling bone density or fragility fracture. If your T-score dropped significantly between scans (e.g., from –2.5 to –3.0 over two years, or 4–5% decline per year), a follow-up scan is warranted to determine if you need to escalate therapy. Similarly, if you fractured since your last DEXA, a new scan documents current bone density and guides drug choice.

3. Request VFA if vertebral fracture is suspected. VFA (vertebral fracture assessment) is a low-radiation lateral spine image performed during DEXA to identify vertebral compression fractures. Many are asymptomatic. Detecting even one fragility fracture upgrades you from osteopenia to "clinical osteoporosis" and changes treatment recommendations. ISCD and AACE endorse VFA in all patients with historical height loss, kyphosis, or T-score ≤–1.0 at age ≥70.

"Kyphoplasty Is Experimental" or "Conservative Therapy Not Exhausted"

What to write in your appeal:

1. Cite Medicare NCD 150.11 and VAPOUR trial. The Medicare national coverage determination (NCD 150.11) covers percutaneous vertebral augmentation (vertebroplasty and kyphoplasty) for acute vertebral compression fractures when performed in the context of clinical studies or under Coverage with Evidence Development. More importantly, the VAPOUR trial (Lancet 2016) was a randomized controlled trial showing balloon kyphoplasty provided statistically significant and clinically meaningful pain reduction versus nonsurgical care at 1 and 3 months.

2. Explain why your fracture is acute and surgery is urgent. Kyphoplasty is most effective within 6–8 weeks of fracture. Document:

- MRI showing bone marrow edema (indicating acute fracture)

- Date of onset of back pain and mechanism (e.g., "sudden onset severe mid-back pain after lifting; X-ray and MRI confirmed acute T12 compression fracture with edema")

- Severity of pain (VAS score, opioid requirement, inability to perform ADLs)

- Failure of conservative care (bed rest, bracing, NSAIDs, opioids) to provide adequate pain relief after 2–4 weeks

Example: "I sustained an acute L1 vertebral compression fracture on [date]. MRI [date] shows bone marrow edema confirming acute fracture. I have been on oxycodone 10 mg q4h, unable to walk more than 10 feet, and bed-bound for three weeks. Conservative care has failed. VAPOUR trial (Lancet 2016) demonstrated kyphoplasty provides superior pain relief and function compared to nonsurgical care. Delaying surgery prolongs suffering and increases complication risk (pneumonia, DVT, deconditioning)."

3. Address "experimental" claim with professional-society endorsements. The American Academy of Orthopaedic Surgeons (AAOS) appropriateness criteria rate kyphoplasty as "appropriate" for acute, painful vertebral compression fractures. The American College of Radiology (ACR) Appropriateness Criteria also support vertebral augmentation. This is not experimental—it is standard of care.

What We Do

We write insurance appeals for patients whose osteoporosis treatment has been denied. We review your DEXA scans, fracture history, prior medications, and comorbidities, then draft a letter citing the specific AACE, ACP, Endocrine Society, ISCD, and FDA sources your insurer's medical director must consider. We include trial data (FREEDOM, FRAME, ARCH, VERO, HORIZON, ACTIVE, VAPOUR), explain why step therapy is inappropriate when you meet very-high-risk criteria, correct misapplications of black-box warnings, and attach supporting records. Our goal is to translate your clinical story into the regulatory and evidence language that overturns denials.

---

Sources

1. American Association of Clinical Endocrinologists. Clinical Practice Guideline for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. Endocr Pract. 2020;26(Suppl 1):1–46. (Updated 2024.)

2. Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023;176(2):224–238.

3. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622.

4. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of Denosumab Therapy for Osteoporosis: A Systematic Review and Position Statement by ECTS. Bone. 2017;105:11–17. (Endocrine Society 2020 reinforcement statement, JCEM.)

5. International Society for Clinical Densitometry. 2019 ISCD Official Positions – Adult. Available at www.iscd.org.

6. Bone Health & Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. 2022.

7. Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190–198.

8. Cummings SR, San Martin J, McClung MR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med. 2009;361(8):756–765. (FREEDOM trial.)

9. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532–1543. (FRAME trial.)

10. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417–1427. (ARCH trial.)

11. Kendler DL, Marin F, Zerbini CAF, et al. Effects of Teriparatide and Risedronate on New Fractures in Post-menopausal Women with Severe Osteoporosis (VERO): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial. Lancet. 2018;391(10117):230–240.

12. Black DM, Delmas PD, Eastell R, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356(18):1809–1822. (HORIZON-Pivotal Fracture Trial.)

13. Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016;316(7):722–733. (ACTIVE trial.)

14. Clark W, Bird P, Gonski P, et al. Safety and Efficacy of Vertebroplasty for Acute Painful Osteoporotic Fractures (VAPOUR): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet. 2016;388(10052):1408–1416.

15. U.S. Food and Drug Administration. FORTEO (teriparatide) Label Revision November 2020, Supplement 021318s053. Removal of boxed warning and two-year duration recommendation.

16. Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD) L39268: Bone Mass Measurement (BMD). Allows DEXA intervals <24 months when medically necessary.

17. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 150.11: Vertebral Augmentation (Percutaneous Vertebroplasty and Percutaneous Balloon Kyphoplasty).